A MULTICENTER STUDY OF NIRAPARIB AS MAINTENANCE THERAPY IN BRCA WILD-TYPE, NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (POLO TRIAL)

1Se Ik Kim*, 2Chel Hun Choi, 3Ji Hyun Kim, 4Yong Jae Lee, 5Jeong-Yeol Park, 6Dong Hoon Suh, 6Yong Beom Kim, 7Jung-Yoon Lim, 8Byung Gie Kim, 9Jae-Weon Kim. 1Seoul National University College of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 2Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 3National Cancer Center, Center for Gynecologic Cancer and Center for Clinical Trial, Goyang-si, Korea, Republic of; 4Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 5Asan Medical Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 6Seoul National University Bundang Hospital, Department of Obstetrics and Gynecology, Seongnam-Si, Korea, Republic of.

Introduction
Poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors have revolutionized the management of ovarian cancer. However, the optimal treatment of BRCA wild-type patients with advanced ovarian cancer remains controversial. The POLO trial aims to investigate the efficacy of niraparib maintenance therapy in patients with BRCA wild-type, newly diagnosed, low-risk advanced ovarian cancer.

Methods
The POLO is a multi-center, investigator-initiated, single-arm, phase IV trial of patients with FIGO stage III-IV high-grade serous or endometrioid ovarian cancer. This study includes patients having both germline and somatic wild-type BRCA1/2 genes, no visible residual tumor after primary cytoreductive surgery, and responses to the postoperative platinum-based combination chemotherapy. Patients who received neoadjuvant chemotherapy are excluded. All enrolled patients are treated with niraparib maintenance therapy for three years or until disease progression, unacceptable toxicity, or withdrawal of patient consent. The primary endpoint is 12-month progression-free survival (PFS) rate. The secondary endpoints are overall survival, PFS, time to first subsequent treatment, time to second progression, time to second subsequent treatment, and safety. All patients should provide tumor slides obtained during cytoreductive surgery for a prospective examination of somatic homologous recombination deficiency and homologous recombination repair gene alterations. Pre- and post-niraparib blood samples will be collected for circulating cell-free DNA analyses. Molecular biomarkers that may indicate clinical response to niraparib will be identified. In total, 102 patients will be recruited from six sites. An interim analysis is planned after recruitment of 68 participants.

Current Trial Status
Accrual is expected to be completed in December 2023, followed by the presentation of results in 2025.

A PHASE III RANDOMIZED CONTROLLED TRIAL IN PRIMARY STAGE THREE AND FOUR OVARIAN CANCER AFTER INTERVAL CYTOREDUCTIVE SURGERY (FOCUS/KOV-HIPEC-04)

1Ji Hyun Kim*, 2Boram Park, 3Jeong-Yeol Park, 4Jung-Yoon Lee, 5Suk-Joon Chang, 6Yoo Young Lee, 7Dae Gy Hong, 8Hyun Woong Cho, 9Jae Yun Song, 10Jung-Yun Kim, 10Sang-Yoon Park, 10Myong Cheol Lim. 1National Cancer Center, Center for Gynecologic Cancer, Goyang, Korea, Republic of; 2Samsung Medical Center, Biomedical Statistics Center, Research Institute for Future Medicine, Seoul, Korea, Republic of; 3Asan Medical Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 4Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 5Ajou University Medical Center, Obstetrics and Gynecology, Suwon, Korea, Republic of; 6Samsung Medical Center, Biomedical Statistics Center, Research Institute for Future Medicine, Seoul, Korea, Republic of; 7Kyungpook National University Chilgok Hospital, Department of Obstetrics and Gynecology, Daegu, Korea, Republic of; 8Korea University Guro Hospital, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 9Korea University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of; 10Center for Gynecologic Cancer, National Cancer Center, Department of Obstetrics and Gynecology, Goyang, Korea, Republic of.

Abstract TP017/#812 Figure 1

A Phase III Randomized Controlled Trial in Primary Stage Three and Four Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS/KOV-HIPEC-04)

ClinicalTrials.gov (NCT05827523)

Primary endpoint: Overall survival
Secondary endpoint: progression-free survival (PFS), cancer-specific survival, time to first subsequent therapy (TFST), safety, and quality of life

Inclusion criteria
- Stage III IV primary epithelial ovarian cancer who required neoadjuvant chemotherapy (NAC)
- Completed NAC 3 cycles with Paclitaxel 135-175mg/m² Carboplatin AUC 5

Interval Cytoreductive Surgery
Patients with complete cytoreduction or residual disease <2.5mm in depth

HIPEC arm (N=260)
Adjuvant Chemotherapy + Maintenance treatment (Bevacizumab or PARP inhibitor)

Control arm (N=260)

Follow up
Every 3 months for 2 years

HIPEC regimen
- Cisplatin 75mg/m²
- 90 minutes, 41.5°C (range, 41-42°C)

Stratification factors
1. Stage
2. Use of PARP inhibitor or not
3. Size of residual disease

Abstract TP017/#812 Figure 1
**Introduction** The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) during interval cytoreductive surgery increases progression-free and overall survival for patients with advanced-stage epithelial ovarian cancer in two randomized controlled trials (OV-HIPEC-01 and KOV-HIPEC-01). The aim of this trial is to identify the survival benefit of HIPEC in advanced ovarian cancer in the era of maintenance therapy of bevacizumab and/or PARP inhibitor.

**Methods** The KOV-HIPEC-04 is a multicenter, 1:1 randomized, phase III trial that will enroll 520 patients with primary epithelial ovarian cancer who completed neoadjuvant chemotherapy. Patients will be randomized at the time of interval cytoreductive surgery with achieving complete cytoreduction or cytoreduction with no more than 2.5 mm depth of residual disease to receive HIPEC (experimental arm, 41.0–42.0°C cisplatin 75 mg/m², 90 minutes) or not (control arm). After recovery from surgery, patients will receive postoperative platinum-based adjuvant chemotherapy followed by maintenance therapy with PARP inhibitor or bevacizumab. The primary endpoint is to evaluate overall survival (OS); secondary objectives are progression-free survival (PFS), cancer-specific survival, time to first subsequent therapy, safety, and quality of life. Assuming that the enrollment period is 5 years and the follow-up period is 3 years, the total number of events required is 263. Based on the log-rank test, the total number of subjects required to prove HR 0.67 with a two-sided alpha of 0.05 and 90% power is 494. 520 patients are finally studied, considering 5% drop-out. ClinicalTrials.gov (NCT05827523)

**Current Trial Status** Not yet Recruiting

---

**Abstract TP018/#822 Figure 1**

A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III TRIAL OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER


1. National Cancer Center, Center for Gynecologic Cancer, Goyang, Korea, Republic of; 2. National Cancer Center, Biostatistics Collaboration Team, Go-Yang si, Korea, Republic of; 3. Busan Paik Hospital, College of Medicine, Inje University, Department of Obstetrics and Gynecology, Busan, Korea, Republic of; 4. Samsung Medical Center, Obstetrics and Gynecology, Seoul, Korea, Republic of; 5. Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 6. Samsung Medical Center, Goyang, Korea, Republic of; 7. Seoul Metropolitan Government Seoul National University Boramae Medical Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 8. Asan Medical Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 9. Soonchunhyang University Cheonan Hospital, Department of Obstetrics and Gynecology, Chung, Korea, Republic of; 10. Pusan National University Hospital, Department of Obstetrics and Gynecology, Pusan, Korea, Republic of; 11. Pusan Yangsan National University Hospital, Department of Obstetrics and Gynecology, Pusan, Korea, Republic of; 12. Chungnam National University Hospital, Department of Obstetrics and Gynecology, Daejeon, Korea, Republic of; 13. Yonsei University Wonju College of Medicine, Department of Obstetrics and Gynecology, Wonju, Korea, Republic of; 14. Ajou University Medical Center, Obstetrics and Gynecology, Suwon, Korea, Republic of; 15. Center for Gynecologic Cancer, National Cancer Center, Department of Obstetrics and Gynecology, Goyang, Korea, Republic of.

10.1136/ijgc-2023-IGCS.478